Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study

BMC Cancer

Volker Ziller²  Ioannis Kyvernitakis²  Dana Knöll²  Astrid Storch²  Olaf Hars¹  Peyman Hadji² 

[1] Olaf Hars Statistical Consulting, Berlin, Germany

[2] Department of Endocrinology, Reproductive Medicine and Osteoporosis, University hospital of Giessen and Marburg GmbH, Marburg, Baldingerstrasse, 35033 Marburg, Germany

关键词: Endocrine treatment;    Breast cancer;    Aromatase inhibitors;    Compliance;    Adherence;   

Others  :  1079584
DOI  :  10.1186/1471-2407-13-407

 received in 2013-01-21, accepted in 2013-08-22,  发布年份 2013

【 摘 要 】

Background

It is known that suboptimal adherence rates may affect endocrine treatments for breast cancer, but little information has been reported whether any efforts to improve treatment adherence have been successful. We designed a randomized, controlled study to investigate the effect of oral or written patient information program on adherence and persistence when receiving an aromatase inhibitor (AI).

Methods

The study cohort included 181 female patients receiving an adjuvant AI treatment randomly assigned to one of three groups. The first group received reminder letters and information booklets, the second group was reminded and informed through telephone calls and the control group received neither. The primary endpoint was the rate at which patients were classified as adhering to treatment after twelve months.

Results

Baseline results showed a well-balanced randomization with no significant differences between groups. After 12 months, 48% (CI 35–62) of the control group, 62.7% (CI 49–75) in the telephone group and 64.7% (CI 51–77) in the letter group were adhering to therapy. A post hoc pooled analysis with a one-way hypothesis for both interventions versus control indicated a significant difference between the groups favouring the intervention (p = 0.039).

Conclusion

The aim of this study was to investigate the efficacy of a simple and practical interventional program in enhancing adherence to breast cancer treatment. Patients receiving additional/supplemental information appeared to have an improved adherence rate even though the differences between groups were not statistically significant for the primary endpoint.

【 授权许可】

   
2013 Ziller et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350(11):1081-1092.
• [2]Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005, 365(9453):60-62.
• [3]Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353(26):2747-2757.
• [4]Balkrishnan R: The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 2005, 43(6):517-520.
• [5]Hadji P: Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010, 73(2):156-166.
• [6]Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-hulin M: Ann Oncol: Practical guidance for the management of aromatase inhibitor-associated bone loss. 2008.
• [7]Krueger KP, Felkey BG, Berger BA: Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc (Wash DC) 2003, 43(6):668-678.
• [8]Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005, 353(5):487-497.
• [9]Rosenow EC III: Patients’ Understanding of and compliance with medications: the sixth vital sign? Mayo Clin Proc 2005, 80(8):983-987.
• [10]Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, Egberts AC, Nortier JW, Guchelaar HJ: Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010, 28(14):2423-2429.
• [11]Fallowfield L: Acceptance of adjuvant therapy and quality of life issues. Breast 2005, 14(6):612-616.
• [12]Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Lin GS, Miles S, Neugut AI: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010, 28(27):4120-4128.
• [13]Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW: Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012, 134(2):459-478.
• [14]Partridge AH, Wang PS, Winer EP, Avorn J: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003, 21(4):602-606.
• [15]Partridge AH, Lafountain A, Mayer E, Taylor BS, Winer E: Asnis-alibozek a. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008, 26(4):556-562.
• [16]Waterhouse DM, Calzone KA, Mele C, Brenner DE: Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993, 11(6):1189-1197.
• [17]Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009, 20(3):431-436.
• [18]Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011, 126(2):529-537.
• [19]Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK: Medication compliance and persistence: terminology and definitions. Value Health 2008, 11(1):44-47.
• [20]Ruddy KJ, Partridge AH: Adherence with adjuvant hormonal therapy for breast cancer. Ann Oncol 2009, 20(3):401-402.
• [21]Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R: Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2000., 2CD000011
• [22]ISPOR: International society for pharmacoeconomics and outcomes research tenth annual international meeting contributed presentation abstracts. Value Health 2005, 8(3):237-419.
• [23]World Health Organisation: Adherence to Long-Term Therapies: Evidence for Action ISBN. WHO-Publications; 2003.
• [24]Albert US, Altland H, Duda V, Engel J, Geraedts M, Heywang-Kobrunner S, Holzel D, Kalbheim E, Koller M, Konig K, Kreienberg R, Kuhn T, Lebeau A, Nass-Griegoleit I, Schlake W, Schmutzler R, Schreer I, Schulte H, Schulz-Wendtland R, Wagner U, Kopp I: Summary of the updated stage 3 guideline for early detection of breast cancer in Germany 2008. Rofo 2008, 180(5):455-465.
• [25]Partridge AH: Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006, 17(2):183-184.
• [26]Demissie S, Silliman RA, Lash TL: Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001, 19(2):322-328.
• [27]Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor–positive breast cancer. J Clin Oncol 2004, 22(16):3309-3315.
• [28]Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA: Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006, 99(2):215-220.
• [29]Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA: Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008, 26(4):549-555.
• [30]Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ: Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007, 109(5):832-839.
• [31]DiIorio C, McCarty F, Resnicow K, McDonnell HM, Soet J, Yeager K, Sharma SM, Morisky DE, Lundberg B: Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. AIDS Care 2008, 20(3):273-283.
• [32]Golin CE, Earp J, Tien HC, Stewart P, Porter C, Howie L: A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J Acquir Immune Defic Syndr 2006, 42(1):42-51.
• [33]Schmaling KB, Afari N, Blume AW: Assessment of psychological factors associated with adherence to medication regimens among adult patients with asthma. J Asthma 2000, 37(4):335-343.